Joseph Group Capital Management Acquires 1,144 Shares of Medpace Holdings, Inc. $MEDP

Joseph Group Capital Management increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 27.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,317 shares of the company’s stock after acquiring an additional 1,144 shares during the quarter. Joseph Group Capital Management’s holdings in Medpace were worth $1,669,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MEDP. Whittier Trust Co. boosted its position in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after purchasing an additional 35 shares during the period. PDS Planning Inc grew its position in shares of Medpace by 1.5% in the second quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock valued at $760,000 after purchasing an additional 35 shares during the last quarter. Benjamin Edwards Inc. increased its stake in shares of Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock worth $366,000 after purchasing an additional 36 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Finally, Assetmark Inc. boosted its stake in Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after purchasing an additional 43 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.5%

Shares of MEDP stock opened at $589.15 on Monday. The firm has a market capitalization of $16.60 billion, a price-to-earnings ratio of 41.20, a PEG ratio of 2.67 and a beta of 1.42. The business’s 50-day moving average price is $527.73 and its 200-day moving average price is $414.12. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $625.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the business earned $3.01 EPS. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Susan E. Burwig sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the transaction, the vice president directly owned 57,500 shares of the company’s stock, valued at $27,600,000. This trade represents a 14.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Stephen P. Ewald sold 15,230 shares of the stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $598.85, for a total value of $9,120,485.50. Following the sale, the general counsel owned 13,343 shares of the company’s stock, valued at approximately $7,990,455.55. The trade was a 53.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 116,211 shares of company stock valued at $63,569,958. 20.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MEDP has been the subject of a number of research reports. Barclays lifted their target price on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a report on Friday, October 24th. TD Cowen upped their target price on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research report on Wednesday, July 23rd. Jefferies Financial Group increased their price target on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. Finally, Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, nine have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $475.90.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.